Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel Free RNAZ Stock Alerts

TransCode Therapeutics (RNAZ) Competitors

TransCode Therapeutics logo
$1.65 -0.07 (-4.07%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.84 +0.19 (+11.27%)
As of 09/18/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RNAZ vs. BNR, BDTX, RANI, GNLX, and PMN

Should you buy TransCode Therapeutics stock or one of its competitors? TransCode Therapeutics's main competitors and comparable companies include Burning Rock Biotech (BNR), Black Diamond Therapeutics (BDTX), Rani Therapeutics (RANI), Genelux (GNLX), and Promis Neurosciences (PMN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TransCode Therapeutics compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

In the previous week, TransCode Therapeutics had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 beat TransCode Therapeutics' score of -0.87 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Burning Rock Biotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TransCode Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative

30.0% of Burning Rock Biotech shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Burning Rock Biotech has higher revenue and earnings than TransCode Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$77.16M1.94-$7.92M-$0.87N/A
TransCode TherapeuticsN/AN/A-$34.66M-$52.37N/A

Burning Rock Biotech has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

TransCode Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Burning Rock Biotech's return on equity of -12.98% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-13.60% -12.98% -8.59%
TransCode Therapeutics N/A -875.35%-37.46%

Summary

Burning Rock Biotech beats TransCode Therapeutics on 9 of the 12 factors compared between the two stocks.

How does TransCode Therapeutics compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Black Diamond Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 422.96%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Black Diamond Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

95.5% of Black Diamond Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Black Diamond Therapeutics has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Black Diamond Therapeutics' return on equity of -32.10% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Black Diamond TherapeuticsN/A -32.10% -25.21%
TransCode Therapeutics N/A -875.35%-37.46%

In the previous week, TransCode Therapeutics had 2 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 2 mentions for TransCode Therapeutics and 0 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.76 beat TransCode Therapeutics' score of -0.87 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Black Diamond Therapeutics Positive
TransCode Therapeutics Negative

Black Diamond Therapeutics has higher revenue and earnings than TransCode Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Black Diamond Therapeutics$70M1.61$22.37M-$0.75N/A
TransCode TherapeuticsN/AN/A-$34.66M-$52.37N/A

Summary

Black Diamond Therapeutics beats TransCode Therapeutics on 12 of the 14 factors compared between the two stocks.

How does TransCode Therapeutics compare to Rani Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

TransCode Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 915.08%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Rani Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

30.2% of Rani Therapeutics shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, TransCode Therapeutics had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 2 mentions for TransCode Therapeutics and 0 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.00 beat TransCode Therapeutics' score of -0.87 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
TransCode Therapeutics Negative
Rani Therapeutics Neutral

Rani Therapeutics' return on equity of -104.60% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TransCode TherapeuticsN/A -875.35% -37.46%
Rani Therapeutics N/A -104.60%-65.17%

Rani Therapeutics has higher revenue and earnings than TransCode Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransCode TherapeuticsN/AN/A-$34.66M-$52.37N/A
Rani Therapeutics$1.63M73.72-$29.67M-$0.27N/A

Summary

Rani Therapeutics beats TransCode Therapeutics on 11 of the 15 factors compared between the two stocks.

How does TransCode Therapeutics compare to Genelux?

TransCode Therapeutics (NASDAQ:RNAZ) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Genelux has a consensus target price of $18.00, indicating a potential upside of 611.46%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Genelux
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

37.3% of Genelux shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Genelux had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 3 mentions for Genelux and 2 mentions for TransCode Therapeutics. Genelux's average media sentiment score of 1.20 beat TransCode Therapeutics' score of -0.87 indicating that Genelux is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransCode Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
Genelux
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Genelux's return on equity of -205.85% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TransCode TherapeuticsN/A -875.35% -37.46%
Genelux N/A -205.85%-138.79%

TransCode Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Genelux has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Genelux has higher revenue and earnings than TransCode Therapeutics. Genelux is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransCode TherapeuticsN/AN/A-$34.66M-$52.37N/A
Genelux$10K11,445.72-$32.15M-$0.86N/A

Summary

Genelux beats TransCode Therapeutics on 12 of the 15 factors compared between the two stocks.

How does TransCode Therapeutics compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

50.1% of Promis Neurosciences shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Promis Neurosciences is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Promis NeurosciencesN/AN/A-$39.72M-$8.54N/A
TransCode TherapeuticsN/AN/A-$34.66M-$52.37N/A

Promis Neurosciences currently has a consensus target price of $34.00, suggesting a potential upside of 142.68%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Promis Neurosciences is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Promis Neurosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, TransCode Therapeutics had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 2 mentions for TransCode Therapeutics and 0 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.00 beat TransCode Therapeutics' score of -0.87 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company Overall Sentiment
Promis Neurosciences Neutral
TransCode Therapeutics Negative

Promis Neurosciences has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Promis Neurosciences' return on equity of -143.09% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Promis NeurosciencesN/A -143.09% -109.15%
TransCode Therapeutics N/A -875.35%-37.46%

Summary

Promis Neurosciences beats TransCode Therapeutics on 9 of the 14 factors compared between the two stocks.

Get TransCode Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNAZ vs. The Competition

Export
MetricTransCode TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$27.94M$3.88B$7.24B$12.95B
Dividend YieldN/A3.64%2.57%12.80%
P/E Ratio-0.0314.23275.4925.40
Price / SalesN/A1,423.44639.5587.39
Price / CashN/A108.9076.2551.42
Price / Book0.1515.4510.466.33
Net Income-$34.66M-$22.86M$3.49B$358.33M
7 Day Performance-2.37%-1.21%0.59%1.12%
1 Month Performance-44.44%-3.29%-1.74%-2.39%
1 Year Performance-85.89%37.74%18.13%5.35%

TransCode Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNAZ
TransCode Therapeutics
0.2863 of 5 stars		$1.65
-4.1%		N/A-85.9%$27.94MN/AN/A12
BNR
Burning Rock Biotech
0.6251 of 5 stars		$11.49
+7.3%		N/A+66.1%$119.83M$514.43MN/A1,390
BDTX
Black Diamond Therapeutics
2.9468 of 5 stars		$2.08
-1.2%		$10.25
+394.0%		-40.2%$119.79MN/AN/A90
RANI
Rani Therapeutics
3.2645 of 5 stars		$0.86
-1.8%		$8.75
+921.0%		+67.4%$119.46M$4.88MN/A110
GNLX
Genelux
2.5596 of 5 stars		$2.54
-0.2%		$18.00
+610.1%		-39.2%$114.70M$8KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RNAZ) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Gold did this exact thing in 1975… [then exploded]
In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...
Golden Portfolio | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel